Wegovy (semaglutide) — a weight‑loss medication

Wegovy (semaglutide) is a weight‑loss medication available as a once‑weekly subcutaneous injection. It helps regulate appetite and reduce calorie intake.

Form and Mechanism of Action

Wegovy is supplied as a solution for subcutaneous injection in pre‑filled pens (2.4 mg, 7.2 mg).

The active ingredient, semaglutide (Semaglutide), is a GLP‑1 receptor agonist that:

• reduces appetite
• slows gastric emptying
• decreases overall food intake
• supports long‑term weight control

Semaglutide acts as an analogue of human GLP‑1 and influences appetite‑regulating centers in the brain, helping reduce caloric consumption.

Structural Characteristics of Semaglutide

The structure of semaglutide is 94% homologous to human GLP‑1, but includes modifications that extend its duration of action:

• substitution of specific amino acids
• fatty‑acid acylation
• resistance to enzymatic degradation

Side Effects and Contraindications

Common side effects include:

• nausea and vomiting
• diarrhea or constipation
• a feeling of heaviness or fullness in the stomach

The medication is contraindicated in individuals with hypersensitivity to semaglutide and in certain medical conditions, including acute pancreatitis. A medical consultation is required before starting therapy.

Effectiveness

When combined with dietary adjustments and physical activity, Wegovy provides significant weight reduction within several weeks. Clinical data confirm sustained weight loss and improved weight control in adults with obesity or overweight.